Eli Lilly announced that it has accepted the recommendation of the ACCELERATE study data monitoring committee to continue the Phase 3 trial of evacetrapib.

The ACCELERATE (Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High Risk for Vascular Outcomes) study, a multi-center, randomized, double-blind, placebo-controlled trial, is evaluating the efficacy and safety of evacetrapib in participants with high-risk atherosclerotic cardiovascular disease (ASCVD). The primary outcome measure is time to first occurrence of any component of the composite cardiovascular events of cardiovascular death, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina. The last patient visit in ACCELERATE is expected in July 2016.

RELATED: First-in-Class Cholesterol-Lowering Drug Approved

Evacetrapib (LY2484595) is a potent and selective inhibitor of cholesteryl ester transfer protein (CETP), with effects on high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, and cholesterol efflux.

For more information call (800) 545–5979 or visit Lilly.com.